Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Juan P Alderuccio, MD
University of Miami
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Cancer Specialists and Research Institute
Fort Myers, Florida, United States
Bradley J Monk, MD, FACSNot, yet, recruiting - University of Miami
Miami, Florida, United States
Juan P Alderuccio, MDRecruiting - University of Michigan
Ann Arbor, Michigan, United States
Yasmin H Karimi, MDRecruiting - Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Matt Matasar, MDRecruiting - Allegheny Health Network
Pittsburgh, Pennsylvania, United States
Cyrus Khan, MDNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Feb 2022
- Primary completion
- 1 Aug 2027
- Completion
- 1 Aug 2030
- Last update posted
- 23 Mar 2026
- Registered enrollment
- 100
- Registry id
- NCT04998669
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.